TMDX
Transmedics Group Inc
NASDAQ · Health Care
$135.06
+5.46 (+4.21%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 428.47M | 2.56B | 2.67B | 2.60B |
| Net Income | 34.41M | 174.28M | 176.17M | 221.55M |
| EPS | — | — | — | — |
| Profit Margin | 8.0% | 6.8% | 6.6% | 8.5% |
| Rev Growth | +144.4% | -4.8% | -8.6% | +8.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.59B | 1.67B | 1.93B | 1.88B |
| Total Equity | 714.95M | 2.09B | 2.11B | 1.74B |
| D/E Ratio | 2.23 | 0.80 | 0.92 | 1.08 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 36.58M | 255.90M | 309.48M | 247.18M |
| Free Cash Flow | — | 177.98M | 251.22M | 206.55M |